Literature DB >> 18040093

A biological substrate for somatoform disorders: importance of pathophysiology.

Joel E Dimsdale1, Robert Dantzer.   

Abstract

Somatoform disorders are troubling to both patients and physicians. The diagnosis regrettably relies on the presence of subjective distress in the absence of objective findings. As a result, there is always the possibility that a diagnosis will be "missed." There is a clear underlying physiology of distress, which implies that there is a two-way street--both psychosomatic and somatopsychic in terms of production and experience of somatoform symptoms. Studies on communication pathways from the immune system to the brain provide exciting new information on the pathophysiology of inflammation-associated symptoms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040093      PMCID: PMC2908292          DOI: 10.1097/PSY.0b013e31815b00e7

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  29 in total

Review 1.  Cytokine-induced sickness behaviour: mechanisms and implications.

Authors:  Jan Pieter Konsman; Patricia Parnet; Robert Dantzer
Journal:  Trends Neurosci       Date:  2002-03       Impact factor: 13.837

2.  Neural correlates of interindividual differences in the subjective experience of pain.

Authors:  Robert C Coghill; John G McHaffie; Yi-Fen Yen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-24       Impact factor: 11.205

Review 3.  Mental precursors of myocardial infarction.

Authors:  A Appels
Journal:  Br J Psychiatry       Date:  1990-04       Impact factor: 9.319

Review 4.  Sensitization associated with stressors and cytokine treatments.

Authors:  Hymie Anisman; Zul Merali; Shawn Hayley
Journal:  Brain Behav Immun       Date:  2003-04       Impact factor: 7.217

Review 5.  Cytokine-induced sickness behavior: where do we stand?

Authors:  R Dantzer
Journal:  Brain Behav Immun       Date:  2001-03       Impact factor: 7.217

6.  Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.

Authors:  L Capuron; A Ravaud; R Dantzer
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

7.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

Authors:  Lucile Capuron; Charles L Raison; Dominique L Musselman; David H Lawson; Charles B Nemeroff; Andrew H Miller
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

8.  Reduced glucocorticoid sensitivity of monocyte interleukin-6 production in male industrial employees who are vitally exhausted.

Authors:  Petra H Wirtz; Roland von Känel; Pia Schnorpfeil; Ulrike Ehlert; Karl Frey; Joachim E Fischer
Journal:  Psychosom Med       Date:  2003 Jul-Aug       Impact factor: 4.312

9.  Prior stressor exposure sensitizes LPS-induced cytokine production.

Authors:  John D Johnson; Kevin A O'Connor; Terrence Deak; Matt Stark; Linda R Watkins; Steven F Maier
Journal:  Brain Behav Immun       Date:  2002-08       Impact factor: 7.217

10.  The effect of opioids on sleep architecture.

Authors:  Joel E Dimsdale; Daniel Norman; Douglas DeJardin; Mark S Wallace
Journal:  J Clin Sleep Med       Date:  2007-02-15       Impact factor: 4.062

View more
  22 in total

Review 1.  Inflammation at the intersection of behavior and somatic symptoms.

Authors:  Michael R Irwin
Journal:  Psychiatr Clin North Am       Date:  2011-09

2.  Childhood somatic complaints predict generalized anxiety and depressive disorders during young adulthood in a community sample.

Authors:  L Shanahan; N Zucker; W E Copeland; C L Bondy; H L Egger; E J Costello
Journal:  Psychol Med       Date:  2014-12-18       Impact factor: 7.723

3.  [Etiopathogenetic aspects of somatoform disorders].

Authors:  M Noll-Hussong; H Gündel
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

4.  Explanatory models of medically unexplained symptoms: a qualitative analysis of the literature.

Authors:  J van Ravenzwaaij; Tc Olde Hartman; H van Ravesteijn; R Eveleigh; E van Rijswijk; Plbj Lucassen
Journal:  Ment Health Fam Med       Date:  2010-12

5.  In vivo β-adrenergic receptor responsiveness: ethnic differences in the relationship with symptoms of depression and fatigue.

Authors:  Frank Euteneuer; Michael G Ziegler; Paul J Mills; Winfried Rief; Joel E Dimsdale
Journal:  Int J Behav Med       Date:  2014

6.  Association of C-reactive protein and interleukin-6 with new-onset fatigue in the Whitehall II prospective cohort study.

Authors:  H J Cho; M Kivimäki; J E Bower; M R Irwin
Journal:  Psychol Med       Date:  2012-11-14       Impact factor: 7.723

7.  [Somatoform disorders with pain as the predominant symptom: results to distinguish a common group of diseases].

Authors:  R Nickel; J Hardt; B Kappis; R Schwab; U T Egle
Journal:  Schmerz       Date:  2009-08       Impact factor: 1.107

Review 8.  Advances in understanding illness anxiety.

Authors:  Kelli J Harding; Natalia Skritskaya; Emily Doherty; Brian A Fallon
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

9.  What do patients with medically unexplained physical symptoms (MUPS) think? A qualitative study.

Authors:  José Nunes; Teresa Ventura; Ricardo Encarnação; Patrícia Rosado Pinto; Isabel Santos
Journal:  Ment Health Fam Med       Date:  2013-06

10.  Elevated concentration of C-reactive protein is associated with pregnancy-related co-morbidities but not with relapse activity in multiple sclerosis.

Authors:  Anna Jalkanen; Tommi Kauko; Janne O Koskinen; Matti E Waris; Laura Airas
Journal:  Neurol Sci       Date:  2014-10-12       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.